Holger Rumpold1,2, M Hackl3, A Petzer4, D Wolf5. 1. Gastrointestinal Cancer Center, Ordensklinikum Linz, Seilerstaette 4, 4010, Linz, Austria. holger.rumpold@ordensklinikum.at. 2. Medical Faculty, Johannes Kepler University, Linz, Austria. holger.rumpold@ordensklinikum.at. 3. National Cancer Registry, Statistics Austria, Vienna, Austria. 4. Department of Medical Oncology and Hematology, Ordensklinikum Linz, Linz, Austria. 5. Internal Medicine 5, Department of Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria.
Abstract
PURPOSE: Incidence and mortality of colorectal cancer (CRC) declined over the last decades. However, survival depends on the primary tumor location. It is unknown if all progress in outcomes vary depending on left-sided (LCRC) versus right-sided (RCC) colorectal cancer. We compare incidence and mortality rates over time according to the primary tumor location. METHODS: Data from the Austrian National Cancer Registry spanning from 1983 to 2018 were used to calculate annual incidence and mortality rates and survival stratified by primary tumor localization and stage. Joinpoint regression with linear regression models were used on different subgroups to identify significant changes of incidence- and mortality slopes. RESULTS: A total of 168,260 (incidence dataset) and 87,355 cases (mortality dataset) were identified. Survival of disseminated RCC was worse compared to LCRC (HR 1.14; CI 1.106-1.169). Total and LCRC incidence and mortality rates declined steadily over time, whereas the rates of RCC did not. Incidence of disseminated RCC declined significantly less (slope - 0.07; CI - 0.086; - 0.055) than in LCRC (slope - 0.159; CI - 0.183; - 0.136); mortality rate of RCC was unchanged over time. Incidence and mortality of localized RCC remained unchanged over time, whereas both rates declined independently of stage in LCRC. CONCLUSION: Colorectal cancer outcomes during the last 35 years have preferentially improved in LCRC but not in RCC, indicating that the progress made is limited to LCRC. It is necessary to define RCC as a distinct form of CRC and to focus on specific strategies for its early detection and treatment.
PURPOSE: Incidence and mortality of colorectal cancer (CRC) declined over the last decades. However, survival depends on the primary tumor location. It is unknown if all progress in outcomes vary depending on left-sided (LCRC) versus right-sided (RCC) colorectal cancer. We compare incidence and mortality rates over time according to the primary tumor location. METHODS: Data from the Austrian National Cancer Registry spanning from 1983 to 2018 were used to calculate annual incidence and mortality rates and survival stratified by primary tumor localization and stage. Joinpoint regression with linear regression models were used on different subgroups to identify significant changes of incidence- and mortality slopes. RESULTS: A total of 168,260 (incidence dataset) and 87,355 cases (mortality dataset) were identified. Survival of disseminated RCC was worse compared to LCRC (HR 1.14; CI 1.106-1.169). Total and LCRC incidence and mortality rates declined steadily over time, whereas the rates of RCC did not. Incidence of disseminated RCC declined significantly less (slope - 0.07; CI - 0.086; - 0.055) than in LCRC (slope - 0.159; CI - 0.183; - 0.136); mortality rate of RCC was unchanged over time. Incidence and mortality of localized RCC remained unchanged over time, whereas both rates declined independently of stage in LCRC. CONCLUSION: Colorectal cancer outcomes during the last 35 years have preferentially improved in LCRC but not in RCC, indicating that the progress made is limited to LCRC. It is necessary to define RCC as a distinct form of CRC and to focus on specific strategies for its early detection and treatment.
Authors: Brian Bressler; Lawrence F Paszat; Zhongliang Chen; Deanna M Rothwell; Chris Vinden; Linda Rabeneck Journal: Gastroenterology Date: 2007-01 Impact factor: 22.682
Authors: Nancy N Baxter; Meredith A Goldwasser; Lawrence F Paszat; Refik Saskin; David R Urbach; Linda Rabeneck Journal: Ann Intern Med Date: 2008-12-15 Impact factor: 25.391
Authors: Brian Bressler; Lawrence F Paszat; Christopher Vinden; Cindy Li; Jingsong He; Linda Rabeneck Journal: Gastroenterology Date: 2004-08 Impact factor: 22.682
Authors: D Arnold; B Lueza; J-Y Douillard; M Peeters; H-J Lenz; A Venook; V Heinemann; E Van Cutsem; J-P Pignon; J Tabernero; A Cervantes; F Ciardiello Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: Nelleke P M Brouwer; Amanda C R K Bos; Valery E P P Lemmens; Pieter J Tanis; Niek Hugen; Iris D Nagtegaal; Johannes H W de Wilt; Rob H A Verhoeven Journal: Int J Cancer Date: 2018-09-29 Impact factor: 7.396
Authors: Ben Schöttker; Rolf Jorde; Anne Peasey; Barbara Thorand; Eugène H J M Jansen; Lisette de Groot; Martinette Streppel; Julian Gardiner; José Manuèl Ordóñez-Mena; Laura Perna; Tom Wilsgaard; Wolfgang Rathmann; Edith Feskens; Ellen Kampman; Galatios Siganos; Inger Njølstad; Ellisiv Bøgeberg Mathiesen; Růžena Kubínová; Andrzej Pająk; Roman Topor-Madry; Abdonas Tamosiunas; Maria Hughes; Frank Kee; Martin Bobak; Antonia Trichopoulou; Paolo Boffetta; Hermann Brenner Journal: BMJ Date: 2014-06-17